Apelin, a novel peptide, was identified as a plasma marker of cardiopulmonary disease, with levels distinguishing cardiac from respiratory causes of symptoms and complementing natriuretic peptide testing.
Key findingPlasma apelin levels differentiated between cardiac and pulmonary disease causes and provided complementary prognostic information alongside natriuret
What the researchers found
Plasma apelin levels differentiated between cardiac and pulmonary disease causes and provided complementary prognostic information alongside natriuretic peptides — a new peptide biomarker for cardiopulmonary disease characterization.
Why it matters
Relevant for neuropeptides, natriuretic-peptides, cardiovascular, respiratory.
How the study worked
cross-sectional study on neuropeptides, natriuretic-peptides.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Apelin: a new plasma marker of cardiopulmonary disease.
Regulatory peptides, 133(1-3), 134-8
Citation
Goetze, Jens Peter; Rehfeld, Jens F; Carlsen, Jørn; Videbaek, Regitze; Andersen, Claus B; Boesgaard, Soeren; Friis-Hansen, Lennart. (2006). Apelin: a new plasma marker of cardiopulmonary disease.. Regulatory peptides, 133(1-3), 134-8.